References
[1] Zanella S, Berti E, Bonometti A, et al. Indeterminate Cell Histiocytosis: a systematic review of the literature with a comprehensive revision of clinical, histopathological, and molecular features. Journal of the European Academy of Dermatology and Venereology, 2023;00:1–17. https://doi.org/10.1111/jdv.19095.
[2] Davick JJ, Kim J, Wick MR et al. Indeterminate dendritic cell tumor: a report of two new cases lacking the ETV3-NCOA2 translocation and a literature review. Am. J. Dermatopathol. 2018; 40: 736–48.
[3] Ma J, Laird J H, Chau K W, et al. Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies. Cancer Medicine, 2019, 8(1): 58-66.
[4] Bubolz AM, Weissinge SE, Stenzinger A, et al. Potential clinical implications of BRAF mutations in histiocytic proliferations. 0ncotarget, 2014, 5(12): 4060-4070.
[5] Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood, 2010, 116(11): 1919-1923.
[6] Kinoshita M, Ogawa Y, Honobe A, et al. Expression of CD1 molecules and colony‐stimulating factor 1 receptor in indeterminate cell histiocytosis. The Journal of Dermatology, 2021, 48(7): 1086-1089.
[7] Penning A J, Al-lbraheemi A, Michal M, et al. Novel BRAF gene fusions and activating point mutations in spindle cell sarcomas with histologic overlap with infantile fibrosarcoma. Modern Pathology, 2021, 34(8): 1530-1540.
[8] Chen D, Su X, Zhu L, et al. Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies. Journal of Translational Medicine, 2023, 21(1): 1-18.
[9] Hussen B M, Azimi T, Abak A, et al. Role of lncRNA BANCR in human cancers: an updated review. Frontiers in Cell and Developmental Biology, 2021, 9: 689992.
[10] Belina M E, Kwock J T, Al-Rohil R, et al. An Atypical Myelomonocytic Cell Infiltrate: Use of Next-Generation Sequencing to Diagnose Indeterminate Cell Histiocytosis. The American Journal of Dermatopathology, 2022, 44(7): 529-531.
[11] Asdourian M S, Shah N, Jacoby T V, et al. Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review. JAMA dermatology, 2022, 158(8): 933-941.
[12] Chen C T, Hu H Y, Chang Y T, et al. Cancer is not a risk factor for bullous pemphigoid: 10‐year population‐based cohort study. British Journal of Dermatology, 2019, 180(3): 553-558.
[13] Shen W C, Chiang H Y, Chen P S, et al. Risk of all-cause mortality, cardiovascular disease mortality, and cancer mortality in patients with bullous pemphigoid. JAMA dermatology, 2022, 158(2): 167-175.
[14] Tegan Nguyen, Julia M, Kwan A, et al. Relationship between radiation therapy and bullous pemphigoid. Dermatology, 2014, 229(2): 88-96.
[15] Akdogan N, Demircan C, Bolek E C, et al. Indeterminate cell histiocytosis in a patient with systemic lupus erythematosus and antiphospholipid antibody syndrome: an unusual association[J]. Lupus, 2020, 29(1): 74-78.